Aussie court tosses Lipitor suit against Pfizer; Novartis nabs FDA approval for multiple myeloma med;

> Pfizer's ($PFE) strategy of offering steep Lipitor rebates as the drug's patent neared expiration didn't constitute anticompetitive conduct, an Australian judge said, tossing a lawsuit filed by the Australian Competition and Consumer Commission. Report (sub. req.)

> Novartis ($NVS) won FDA approval for its multiple myeloma drug Farydak, as a third line treatment. Report

> The global cancer drug market is expected to hit $111 billion by 2020, new market research shows. Report

> Hospira ($HSP) and Celltrion launched their biosimilar versions of Remicade in Europe, where the brand earned €2 billion last year. Report (reg. req.)

And Finally... Preventive treatment with an HIV drug reduced infection by 86% in gay men at high risk of contracting the disease. Report

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.